AMRI has announced today that Junan Guo, Ph.D. has joined the company as senior director, analytical and quality services. Dr. Guo fills the role vacated by Dr. Steven Hagen, who was promoted to vice president of pharmaceutical development and manufacturing in September 2008. Dr. Guo will oversee all domestic analytical chemistry, preformulation and formulation, quality assurance and regulatory affairs efforts, including support related to early stage discovery and preclinical development, as well as the manufacturing of clinical trial materials, intermediates, and commercial active pharmaceutical ingredients. This includes developing analytical methods to test the purity of clinical trial candidates and commercial products manufactured at AMRI. He will provide leadership to a team of over 100 skilled scientists and quality professionals, and work closely with customers. Prior to joining AMRI, Dr. Guo was director, analytical development at Patheon. There, he managed a scientific staff of about 170 individuals at multiple locations responsible for supporting contract dosage form development and manufacturing services. He began his tenure at Patheon in 1999 in the role of supervisor, analytical development. Prior to Patheon, he worked at Genpharm, Inc. in Toronto, Canada in the areas of analytical R&D and technology transfer. Dr. Guo earned a Ph.D. in physical organic chemistry from The University of Western Ontario. He also holds a master’s degree in medicinal chemistry from the Chinese Academy of Medical Sciences in Beijing, and a bachelor’s degree in chemistry from Beijing Normal University. AMRI Vice President, Pharmaceutical Development and Manufacturing Steven Hagen said, “We are pleased that Dr. Guo is joining our team as he has considerable CRO experience in pharmaceutical development and he is also trained in Lean Six Sigma techniques. These experiences will greatly aid our expansion plans and efficiency efforts across the AMRI development and manufacturing spectrum.”
